about
Nanomedicine approaches for corneal diseasesRecent advances in dendrimer-based nanovectors for tumor-targeted drug and gene deliverySynthesis of surface-modified TREN-cored PAMAM dendrimers and their effects on the solubility of sulfamethoxazole (SMZ) as an analog antibiotic drug.PAMAM dendrimers and branched polyethyleneglycol (nanoparticles) prodrugs of (-)-beta-D-(2R, 4R)-dioxolane-thymine (DOT) and their anti-HIV activity.Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis.Enabling individualized therapy through nanotechnologyClick hybridization of immune cells and polyamidoamine dendrimersPEGylated polyamidoamine dendrimers with bis-aryl hydrazone linkages for enhanced gene delivery.FACILE PREPARATION OF NANOPARTICLES BY INTRAMOLECULAR CROSSLINKING OF ISOCYANATE FUNCTIONALIZED COPOLYMERS.mPEG-PAMAM-G4 nucleic acid nanocomplexes: enhanced stability, RNase protection, and activity of splice switching oligomer and poly I:C RNA.Design and exploratory data analysis of a second generation of dendrimer prodrugs potentially antichagasic and leishmanicide.A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.Study of interaction energies between the PAMAM dendrimer and nonsteroidal anti-inflammatory drug using a distributed computational strategy and experimental analysis by ESI-MS/MS.Dendrimers for pharmaceutical and biomedical applications.The transferrin receptor and the targeted delivery of therapeutic agents against cancer.Biodegradable polydisulfide dendrimer nanoclusters as MRI contrast agents.Targeted nanosystems: Advances in targeted dendrimers for cancer therapyDendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Prolonged drug delivery system of an antifungal drug by association with polyamidoamine dendrimers.Dendritic systems in drug delivery applications.Past and future evolution in colloidal drug delivery systems.Drug nanoparticles: formulating poorly water-soluble compounds.Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture.Electrospun blends of gelatin and gelatin-dendrimer conjugates as a wound-dressing and drug-delivery platform.Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals.Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.Transdermal drug delivery: from micro to nano.Image-guided nanosystems for targeted delivery in cancer therapy.Perspectives and potential applications of nanomedicine in breast and prostate cancer.Dendrimers - from organic synthesis to pharmaceutical applications: an update.Nanodrugs: pharmacokinetics and safety.Topical delivery of ocular therapeutics: carrier systems and physical methods.Dendrimers for gene delivery--a potential approach for ocular therapy?Therapeutic face of RNAi: in vivo challenges.Applications of dendrimers for brain delivery and cancer therapy.Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes).Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers.Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells.Capillary electrophoresis and nanomaterials - Part I: Capillary electrophoresis of nanomaterials.Size-dependant cellular uptake of dendritic polyglycerol.
P2860
Q27022253-F7F6BDE0-E7AD-4D26-A4BA-EF3F3823131EQ28085438-8DC4C5D4-8A01-4BCC-8D20-1636D1505943Q31119728-4D3DF7C2-9E6E-4112-AD38-A3CA68242421Q33270151-F7BB4240-99DA-435B-A065-B0680DF0DD6DQ33622573-BB25E608-1691-4FA1-842A-B8FA8092ED5EQ33917755-2C6F3EB8-FCF6-44C9-8B10-BCE426FFA966Q34047132-EA254CEB-DA74-47DF-87FE-1BA205D2FF13Q34054137-9CDEF4BA-7EEF-4248-B265-A6A8CA2EE306Q34067363-0F527F9A-A9A5-4CDA-B6F1-7887954E85A9Q34972145-1AB2E484-6618-4D8A-99FE-A9BBF45202A4Q34976879-76F02073-D2C7-4020-AA0E-4116AD7B21EEQ35130646-A134200C-FD6B-467E-82F0-CC2DDA31E8CDQ35808333-90CCA29F-40F3-4CA0-9B41-05897EFD7E4DQ36367723-90B9A944-6A30-4314-B943-2DD8743D7388Q36406637-EFE6685E-8967-41D1-9F36-756CA372429BQ36429106-717D296E-F5BD-48F8-B72A-5152D6DC0D6DQ36679983-0DB2ABBB-AF8E-4BC9-B01E-44ADC97FBF1AQ36690711-C68AC696-1CB0-446F-9010-719C305FB3DCQ36701572-D5A10879-62E9-43FF-9998-FE187EA5D920Q36945843-EDF6EB8B-C808-4F03-9F42-FF4AF631CCF3Q37039030-09F6A8C5-8D78-4A3C-A46F-FECC5E917371Q37109079-219522DC-B62A-4883-A234-0977E9EA07D2Q37381198-762BF1D9-5F38-4F84-9182-34B5F350077AQ37454984-91478F87-4C59-406B-953D-112E8C35AA0FQ37694413-FA19B416-F410-49F4-9075-E580CC0E8D22Q37834336-49B2AA2C-D6E2-4EFA-A166-B491F7F8F4D8Q37984016-10774CE0-B6DD-43C5-9819-71448B9C3AC0Q38011794-E365BC3B-6171-4D9A-BC4E-5BA36D1BB1FDQ38067306-1EF7D6B7-F949-40E6-BC24-529738E03E83Q38168279-7FBFAB31-FC26-4AA1-9C2C-3F3D2AAB973BQ38193067-9F899C2F-14B1-4925-964B-3AB0F0218E9DQ38196446-19C9C892-7EAC-42E6-B179-660C6DEA2A9EQ38196447-DCE1154E-3075-4114-A547-D8701882487DQ38268541-7FAF8D0C-0672-47D8-ACA9-811F7CFB7870Q38270096-F6090376-3B94-48AF-B3E6-45F9D045DB34Q38314325-6988FAAB-B238-4952-8C1E-D4BCBB017005Q38690866-09490EAE-D3FD-49AD-A1FF-CC36D8C60788Q38940163-CE496CC5-BCA5-4356-815D-C717190CC765Q39407054-015CBB10-16EB-45E2-AEBC-BC66E56AB814Q39588764-FD04A3D2-84F9-4882-A711-DB5E8C698C01
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Designing dendrimers for drug delivery.
@ast
Designing dendrimers for drug delivery.
@en
type
label
Designing dendrimers for drug delivery.
@ast
Designing dendrimers for drug delivery.
@en
prefLabel
Designing dendrimers for drug delivery.
@ast
Designing dendrimers for drug delivery.
@en
P1476
Designing dendrimers for drug delivery.
@en
P2093
P304
P356
10.1016/S1461-5347(99)00203-5
P50
P577
1999-10-01T00:00:00Z